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MULTI-CENTER REGISTRY OF PERCUTANEOUS CORONARY ROTATIONAL 
ABlATION USING THE ROTABLATOR. 
Maurice Buchbinder, David Warth, Wm. O’Neill, Nedim 
Zacca, Robert Ginsburg, niche1 Bertrand, Raimund Erbel, 
an Fourrier, Martin Leon, University of California 
edical Center, San Diego, CA, ‘USA 
Prom January 1988 to 1990, 315 patients with 366 
lesions were entered a multi-center study o 
Percutaneous Coronary Rotational Ablation (QTC 
the Rotablator (R) (Heart Technology, Inc.). R is a 
high speed (160-190.000 rpm) rotational catheter with a 
diamond microcrystal tip which ablates inelastic 
atherosclerotic plaque while sparing normal elastic 
tissue. There were 249 males and 66 females with an 
average age of 61 (33-87). Lesions were located in the 
LAD/DIAG 45%. RCA/PDA 36%, CX/OM 16% and lH 3%. Of all 
lesions, 87% were complex (type B or C). Acute success 
defined as <SO% residual stenosis was achieved in 95% of 
patients. Adjunctive PTCA was performed in 32% of 
lesions primarily to achieve maximal luminal diameter in 
larger arteries. Clinically significant complications 
include non-Q MI in 4.8% urgent CABG in 1.6% and Q-wave 
MI in 0.9%. There were no deaths. Long term (> 6 
months) angiographic follow-up was performed in 94% of 
eligible patients (152/162) showing a restenosis rate 
(defined as < 50% residual stenosis at the treatment 
site) of 32%. 
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TAC~C~~A 
, Rosa 
ge of 
opson, James B. 
he, Iowa “,iey, 
Martins, Univ. 
IA. 
ic therapy deemed effectfve by 
electrophysiologic testing (EPT) has been reported to 
Qroduce better l-2 year survival in patients with 
inducfble sustained monomotphfc ventricular tachycardia 
(VT); longer follow-up has not been reported. We 
therefore followed all patients with heart disease and 
VT studied ae our institution before 1985. Charts were 
er ejection fraction. Sudden 
Ceath free su s also greater (pe.001) and 
continued to 
when ET was continued. 
had an effective response at EQT and who then died 
suddenly showed 3 hsd subtherapeutic drug levels and 2 
stopped therapy prior to death. Conclusion: An 
sponse to therapy determined by EPT 
proved sudden and all cause of death free 
over 7 years if effective therapy was 
cant inued. Patients with an effective response at EPT 
may still be at risk for sudden death if drug levels 
become subtherapeutic. 
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We hypothesized that electrophysiologic study (EPS) guided suppression 
of ventricular tachycardia (VT) of cycle length+< 250 ms does not predict 
subsequent efficacy. We analyzed 8rZ consecut)ve patients who had sus- 
tained monomorphic VT induced at baseline EPS. patients had an average 
of I .6 follow up EPS drug trials. Thirty-one patients (Group I) had a VT 
cycle length < to 250 ms. Fifty-three patients (Group II) had a VT cycle 
leng’h + 250 ms. age - 63 years, mean ejection fraction - 31%. and 
frequency of car artery disease - 90% were similar in Groups I and 
II. Patients were followed an average of 17 months after EPS. Subsequent 
arrhythmic events were defined as sudden cardiacdeath, documented sus- 
tained VT, syncope. or symptomatic automatic implantable cardioverter 
defibrillator discharge. In Group 1, subsequent arrhythmic events occur- 
red in 6 of 13 patients with successful EPS guided drug therapy compared 
with 6 of 18 patients without successful EPS guided drug therapy (P = 
NS). In Group II, subsequent arrhythmic events occurred in 1 of 13 
patients with successful EPS guided therapy compared with 19 of 41 
patients without successful EPS guided drug therapy (p, = .03). 
CONCLWSlONS Successful EPS guided drug therapy 
able long-term outcome in those patients with a VT c 
250 ms. k~ those patients with a VT cycle length 5 250 ms, successful EPS 
guided drug therapy did not predict an arrhythmia-free long-term 
Conclusion: QTCRA is a safe and effective treatment outcome. 
modality with 
term patency. 
excellent initial results and good long 
